Targeted therapy in the treatment of uterine serous carcinoma

Pharmacogenomics

Volumn 16, Issue 2, 2015, Pages 97-99

  Schwab, Carlton L ^a   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HER2; mTOR; PIK3CA; targeted therapy; uterine serous carcinoma

Indexed keywords

AFATINIB; APITOLISIB; AZD 8055; LAPATINIB; NERATINIB; PROTEIN TYROSINE KINASE INHIBITOR; TASELISIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE REGULATION; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TREATMENT FAILURE; ENDOMETRIUM CANCER; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENOMIC INSTABILITY; GROWTH INHIBITION; HER2 GENE; HUMAN; NON SMALL CELL LUNG CANCER; NONHUMAN; PIK3CA GENE; REVIEW; SURVIVAL RATE; TP53 GENE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; UTERUS CARCINOMA; UTERUS SARCOMA; CYSTADENOCARCINOMA, SEROUS; DRUG EFFECTS; FEMALE; GENETICS; MOLECULARLY TARGETED THERAPY; PROCEDURES; UTERINE NEOPLASMS;

ANTINEOPLASTIC AGENTS; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE AMPLIFICATION; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR, ERBB-2; UTERINE NEOPLASMS;

EID: 84921686916     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.176     Document Type: Review

References (20)

1. American Cancer Society. Cancer Facts and Figures 2014, American Cancer Society, Atlanta, GA, USA 2014. www.cancer.org
2. Hamilton CA, Cheung MK, Osann K et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared with grade 3 endometrioid corpus cancers. Br. J. Cancer 94(5), 642-646 (2006).
3. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am. J. Surg. Pathol. 6(2), 93-108 (1982).
4. El-Sahwi KS, Schwartz PE, Santin AD. Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer. Expert Rev. Anticancer Ther. 12(1), 41-49 (2012).
5. Zhao S, Choi M, Overton JD et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc. Natl Acad. Sci. USA 110 (8), 2916-2921 (2013).
6. Buza N, English DP, Santin AD, Hui P. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Mod. Pathol. 26(12), 1605-1612 (2013).
7. Fleming GF, Sill M W, Darcy KM et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 116(1), 15-20 (2010).
8. English DP, Bellone S, Schwab CL et al. T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. Cancer Med. 3(5), 1256-1265 (2014).
9. Scaltriti M, Rojo F, Ocana A et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl Cancer Instit. 99(8), 628-638 (2007).
10. Growden WB, Digloria C, Borger D et al. HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant. Reprod. Sci. 21, 94A (2014).
11. Todeschini P, Cocco E, Bellone S et al. Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. Br. J. Cancer 105 (8), 1176-1182 (2011).
12. Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplifed breast cancer: mechanisms and clinical implications. Crit. Rev. Oncogen. 17(1), 1-16 (2012).
13. Schwab CL, Bellone S, English DP et al. Afatinib demonstrates remarkable activity against HER2-amplifed uterine serous endometrial cancer in vitro and in vivo. Br. J. Cancer 111(9), 1750-1756 (2014).
14. Schwab CL, English DP, Roque DM et al. Neratinib shows effcacy in the treatment of HER2/neu amplifed uterine serous carcinoma in vitro and in vivo. Gynecol. Oncol. 135(1), 142-148 (2014).
15. Sequist LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31(27), 3327-3334 (2013).
16. English DP, Roque DM, Carrara L et al. HER2/neu gene amplifcation determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. Gynecol. Oncol. 131(3), 753-758 (2013).
17. English DP, Bellone S, Cocco E et al. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifcations determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). Am. J. Obstetr. Gynecol. 209(5), 465.e1-9 (2013).
18. Lopez S, Schwab CL, Cocco E et al. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplifed uterine serous carcinoma in vitro and in vivo. Gynecol. Oncol. 135(2), 312-317 (2014).
19. Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, Phase 3 trial. Lancet 379(9816), 633-640 (2012).
20. Groeneweg JW, Hernandez SF, Byron VF et al. Dual HER2 targeting impedes growth of HER2 gene-amplifed uterine serous carcinoma xenografts. Clin. Cancer Res. 20(24), 6517-6528 (2014).